--- title: 'Life Sciences Daily Summary: What Happened on October 7, 2026' headline: Taiho’s lung cancer combination extends progression-free survival in Phase 3 description: Caribou is closing after it couldn’t fund a planned Phase 3 lymphoma trial and will stop development of its two cell therapies. url: https://thebench.bio/news/summaries/2026-10-07 topic: all date: '2026-10-07' covers: - '2026-10-07' date_published: '2026-10-07T12:03:54Z' date_modified: '2026-10-07T12:03:54Z' sources: 3 publisher: The Bench (thebench.bio) --- # Life Sciences Daily Summary: What Happened on October 7, 2026 **Taiho’s lung cancer combination extends progression-free survival in Phase 3** Caribou is closing after it couldn’t fund a planned Phase 3 lymphoma trial and will stop development of its two cell therapies. ## Today in brief Taiho Oncology’s Harold Keer said the Phase 3 trial of zipalertinib plus chemotherapy met its primary endpoint, with median progression-free survival of 14.5 months versus 8.5 months on chemotherapy alone. [1] Caribou Biosciences is shutting down after failing to raise funds for a planned Phase 3 lymphoma trial and will end clinical development of its two CRISPR-based CAR-T therapies. [2] ## Taiho reports longer progression-free survival with zipalertinib combination Harold Keer, Taiho Oncology’s chief medical officer, said the Phase 3 REZILIENT3 trial met its primary endpoint, with median progression-free survival of 14.5 months on zipalertinib plus chemotherapy and 8.5 months on chemotherapy alone. [1] The result was statistically significant, with a hazard ratio of 0.50 and a 95% confidence interval of 0.34 to 0.73, Keer said. [1] Overall survival results are immature, Keer said, and median survival could not be estimated in either group. [1] By the data cutoff, 24 of 140 patients in the combination group and 31 of 139 in the chemotherapy group had died. [1] Keer said 64.2% of patients assigned to chemotherapy had switched to zipalertinib after disease progression, which could reduce the observed difference between groups. [1] The combination caused more adverse events, mostly myelosuppression, or reduced blood-cell production, and more grade 3 or higher events. [1] Keer said these effects were most pronounced during the first four treatment cycles and were managed with dose reductions or treatment discontinuations. [1] Three treatment-related deaths occurred in the combination group, compared with none in the chemotherapy group. [1] The trial is continuing, with later overall-survival analyses planned as more progression or survival events occur. [1] ## Caribou to close after failing to fund planned lymphoma trial Caribou Biosciences said it is shutting down after it could not secure funding for a planned Phase 3 trial of its off-the-shelf CAR-T therapy for lymphoma. [2] The company plans to end clinical development of both its CRISPR-based CAR-T therapies, including vispa-cel for advanced B-cell non-Hodgkin lymphoma. [2] Caribou worked with the FDA over the past year to finalize the Phase 3 design for vespa-cel. [2] Chief executive Rachel Haurwitz told STAT that raising money for the trial had proved too difficult. [2] ## Also worth knowing - Adecto and Aviceda are winding down, according to a report published October 7. [3] ## The day in numbers - **14.5 vs. 8.5 months**: Median progression-free survival with Taiho’s zipalertinib combination versus chemotherapy alone in REZILIENT3. [1] - **64.2%**: Share of patients assigned to chemotherapy who switched to zipalertinib after disease progression. [1] ## Sources 1. [Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo](), Clinical Trials Arena, 2026-10-07 2. [STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down](), STAT Biotech, 2026-10-07 3. [Adecto, Aviceda wind down, as Caribou seeks options](), pharmaphorum, 2026-10-07 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: